326 related articles for article (PubMed ID: 6896278)
1. SIN-1, the main metabolite of molsidomine, inhibits prostaglandin endoperoxide analogue- and arachidonic acid-induced platelet aggregation as well as platelet thromboxane A2 formation.
Block HU; Förster W; Heinroth I
Arzneimittelforschung; 1982; 32(3):189-94. PubMed ID: 6896278
[TBL] [Abstract][Full Text] [Related]
2. The effects of molsidomine and its metabolite SIN-1 on coronary vessel tone, platelet aggregation, and eicosanoid formation in vitro--inhibition of 12-HPETE biosynthesis.
Darius H; Ahland B; Rücker W; Klaus W; Peskar BA; Schrör K
J Cardiovasc Pharmacol; 1984; 6(1):115-21. PubMed ID: 6199592
[TBL] [Abstract][Full Text] [Related]
3. [Effects of SIN-1, a metabolite of molsidomine, on paf-acether-blood platelets interactions].
Nunez D; Russo-Marie F; Benveniste J
Pathol Biol (Paris); 1987 Feb; 35(2 Pt 2):215. PubMed ID: 3550639
[TBL] [Abstract][Full Text] [Related]
4. Influence of trapidil derivatives on arachidonic acid- and prostaglandin endoperoxide analogue- induced platelet aggregation and thromboxane A2 formation.
Heinroth I; Block HU; Mest HJ
Biomed Biochim Acta; 1984; 43(8-9):S389-92. PubMed ID: 6440555
[TBL] [Abstract][Full Text] [Related]
5. [The modification of the biosynthesis and effect of thromboxane A2 and prostacyclin by trapidil (Rocornal)].
Block HU; Heinroth I; Giessler C; Pönicke K; Mentz P; Zehl U; Rettkowski W; Dunemann A; Förster W
Biomed Biochim Acta; 1983; 42(2-3):283-99. PubMed ID: 6411078
[TBL] [Abstract][Full Text] [Related]
6. Effect of molsidomine, an anti-anginal drug, on arachidonic acid metabolism in human platelets.
Croset M; Lagarde M
Biomed Biochim Acta; 1984; 43(8-9):S354-7. PubMed ID: 6440549
[TBL] [Abstract][Full Text] [Related]
7. The influence of molsidomine and its active metabolite SIN-1 on fibrinolysis and platelet aggregation.
Basista M; Grodzińska L; Swies J
Thromb Haemost; 1985 Dec; 54(4):746-9. PubMed ID: 3911480
[TBL] [Abstract][Full Text] [Related]
8. Influence of propranolol, pindolol, practolol and talinolol on arachidonic acid (AA)- and U-46619-induced aggregation and on AA-induced thromboxane A2 formation in platelets.
Heinroth I; Block HU; Pönicke K; Förster W
Prostaglandins Leukot Med; 1983 Oct; 12(2):189-206. PubMed ID: 6139824
[TBL] [Abstract][Full Text] [Related]
9. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
[TBL] [Abstract][Full Text] [Related]
10. Influence of aspirin, molsidomine, trapidil, and some trapidil derivatives on arachidonic acid induced reversible thrombocyte aggregation in the rabbit.
Zehl U; Mest HJ; Förster W
Biomed Biochim Acta; 1984; 43(8-9):S381-4. PubMed ID: 6440554
[TBL] [Abstract][Full Text] [Related]
11. [Thrombocyte interaction with a collagen substrate: the role of thrombocyte-synthesized prostaglandin endoperoxides and thromboxane A2].
Mazurov AB; Leĭtin VL; Repin VS
Biull Eksp Biol Med; 1984 Nov; 98(11):563-6. PubMed ID: 6439262
[TBL] [Abstract][Full Text] [Related]
12. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
[TBL] [Abstract][Full Text] [Related]
13. [Synthesis of thromboxane A2: limiting stages of primary thrombocyte aggregation in humans initiated by arachidonic acid and its metabolic products].
Mevkh AT; Basevich VV; Varfolomeev SD
Biokhimiia; 1984 Dec; 49(12):2035-40. PubMed ID: 6441604
[TBL] [Abstract][Full Text] [Related]
14. Arachidonic acid-induced platelet aggregation and thromboxane A2 generation in patients with coronary heart disease.
Szczeklik A; Gryglewski RJ; Musiał J; Grodzínska L; Serwónska M; Wójcik-Switek L; Marcinkiewicz E
Acta Biol Med Ger; 1978; 37(5-6):741-2. PubMed ID: 742286
[TBL] [Abstract][Full Text] [Related]
15. [Studies on the inhibitory effect of etafenone hydrochloride on platelet aggregation].
Ujiie A; Komatsu H; Kubota T; Hamano S; Naito J
Nihon Yakurigaku Zasshi; 1983 Jun; 81(6):493-8. PubMed ID: 6618341
[TBL] [Abstract][Full Text] [Related]
16. Aggregation and inhibition of rat platelets, and the formation of endoperoxide metabolites.
Hwang DH
Prostaglandins Med; 1980 Sep; 5(3):163-73. PubMed ID: 7413850
[TBL] [Abstract][Full Text] [Related]
17. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction.
Parise LV; Venton DL; Le Breton GC
J Pharmacol Exp Ther; 1984 Jan; 228(1):240-4. PubMed ID: 6319669
[TBL] [Abstract][Full Text] [Related]
18. Antagonism of thromboxane A2/prostaglandin H2 by 13-azaprostanoic acid prevents platelet deposition to the de-endothelialized rabbit aorta in vivo.
Le Breton GC; Lipowski JP; Feinberg H; Venton DL; Ho T; Wu KK
J Pharmacol Exp Ther; 1984 Apr; 229(1):80-4. PubMed ID: 6423815
[TBL] [Abstract][Full Text] [Related]
19. Effects of 2-indolecarbohydrazides on thromboxane synthetase activity and on in vitro and ex vivo blood platelet aggregation. New selective inhibitors.
Monge A; Erro A; Parrado P; Font M; Aldana I; Rocha E; Fernandez-Alvarez E
Arzneimittelforschung; 1986 Aug; 36(8):1184-6. PubMed ID: 3096343
[TBL] [Abstract][Full Text] [Related]
20. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
Patscheke H; Stegmeier K
Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
